Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $20.40 Average Target Price from Analysts

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $20.40.

TARA has been the topic of a number of analyst reports. Piper Sandler initiated coverage on shares of Protara Therapeutics in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $24.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a report on Wednesday, December 3rd.

Protara Therapeutics Stock Down 0.6%

Shares of NASDAQ:TARA opened at $5.01 on Friday. The firm has a market cap of $258.67 million, a P/E ratio of -3.50 and a beta of 1.42. Protara Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.82. The business has a fifty day simple moving average of $5.81 and a 200 day simple moving average of $4.51.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. As a group, equities research analysts expect that Protara Therapeutics will post -3.32 EPS for the current year.

Hedge Funds Weigh In On Protara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TARA. Los Angeles Capital Management LLC bought a new stake in shares of Protara Therapeutics in the 2nd quarter valued at $47,000. Geode Capital Management LLC grew its holdings in Protara Therapeutics by 114.7% in the second quarter. Geode Capital Management LLC now owns 744,519 shares of the company’s stock worth $2,256,000 after purchasing an additional 397,822 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in Protara Therapeutics in the second quarter valued at $30,000. Intech Investment Management LLC bought a new stake in Protara Therapeutics in the second quarter valued at $49,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Protara Therapeutics during the second quarter valued at about $46,000. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.